News NHS under fire for delaying access to rare disease cholester... Pharma concerned by fairness and transparency of NHS England's Prioritisation Framework
Articles NICE calls the shots on Harvoni – but NHS England eyeing pri... Harvoni and rival hep C drugs look set for approval in England – but NHS England may have the last word on controlling costs, finds Andrew McConaghie.
Articles Market access for specialist medicines in the UK: the Price ... A recent pharmaphorum webinar brought four experts together to discuss the future of market access for specialist medicines in the UK.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
